Compare

ANI Pharmaceuticals Inc vs Collegium Pharmaceutical, Inc vs Corcept Therapeutics Inc vs Emergent BioSolutions Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal year	ANI Pharmaceuticals Inc ANIP	Collegium Pharmaceutical, Inc COLL	Corcept Therapeutics Inc CORT	Emergent BioSolutions Inc. EBS
Year ended	2025-12-31	2025-12-31	2025-12-31	2025-12-31
Revenue	$883.37M	$780.57M	$761.41M	$742.90M
Revenue growth (YoY)	+43.8%	+23.6%	+12.8%	-28.8%
Gross margin	n/a	59.3%	n/a	56.1% (computed)
Operating margin	12.6%	23.0%	5.9%	13.5%
Net margin	8.9%	8.1%	13.1%	7.1%
Net income	$78.34M	$62.87M	$99.65M	$52.60M
EPS (Diluted)	$3.32	$1.73	$0.82	$0.93
Operating cash flow	$185.22M	$329.32M	$142.00M	$170.60M
Free cash flow	$171.39M	$327.58M	$141.78M	$156.80M
Cash & equivalents	$285.58M	$231.25M	$120.50M	$205.40M
Total assets	$1.44B	$1.66B	$836.65M	$1.32B
Total liabilities	$899.65M	$1.36B	$188.85M	$796.00M
Shareholders' equity	$540.72M	$301.68M	$647.80M	$522.60M
Return on year-end equity	14.5%	20.8%	15.4%	10.1%
Shares outstanding	22.49M	31.71M	105.97M	52.10M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal year	ANI Pharmaceuticals Inc	Collegium Pharmaceutical, Inc	Corcept Therapeutics Inc	Emergent BioSolutions Inc.
Latest	$883.37M Ended 2025-12-31	$780.57M Ended 2025-12-31	$761.41M Ended 2025-12-31	$742.90M Ended 2025-12-31
1 year earlier	$614.38M Ended 2024-12-31	$631.45M Ended 2024-12-31	$675.04M Ended 2024-12-31	$1.04B Ended 2024-12-31
2 years earlier	$486.82M Ended 2023-12-31	$566.77M Ended 2023-12-31	$482.38M Ended 2023-12-31	$1.05B Ended 2023-12-31
3 years earlier	$316.38M Ended 2022-12-31	$463.93M Ended 2022-12-31	$401.86M Ended 2022-12-31	$1.12B Ended 2022-12-31
4 years earlier	$216.14M Ended 2021-12-31	$276.87M Ended 2021-12-31	$365.98M Ended 2021-12-31	$1.77B Ended 2021-12-31